Pain, agitation, delirium, and neuromuscular blockade in the intensive care unit (ICU)





This chapter will review recommendations from the 2013 Society of Critical Care Medicine and recently published research 1 ( Fig. 22.1 ).




Figure 22.1


Pain, agitation, delirium.


Pain





  • Greater than 50% of intensive care unit (ICU) survivors report significant pain during their ICU stay



  • Common causes of pain in the ICU: acute trauma, injury or burns, postoperative pain, cancer pain, invasive procedures, and routine nursing care such as endotracheal tube suctioning, wound care, and tube insertion



  • Short-term consequences of unrelieved pain: catabolic hypermetabolism, increased circulating catecholamines, impaired tissue perfusion, and decreased immune function



  • Long-term consequences of unrelieved pain: chronic pain, lower health-related quality of life, neuropathic pain, and posttraumatic stress disorder



  • Analgosedation: analgesia-first or analgesia-based sedation (treat with an opioid before a sedative)



  • Assessment: assess pain q4–6h using either the Behavioral Pain Scale or Critical-Care Pain Observation Tool ( Tables 22.1 and 22.2 )



    Table 22.1

    Behavioral Pain Scale (BPS) a














































    ITEM DESCRIPTION SCORE



    • Facial expression




    • Relaxed




    • 1




    • Party tightened (e.g., brow lowering)




    • 2




    • Fully tightened (e.g., eyelid closing)




    • 3




    • Grimacing




    • 4




    • Upper limbs




    • No movement




    • 1




    • Partly bent




    • 2




    • Fully bent with finger flexion




    • 3




    • Permanently retracted




    • 4




    • Compliance with ventilation




    • Tolerating movement




    • 1




    • Coughing but tolerating ventilation most of the time




    • 2




    • Fighting ventilator




    • 3




    • Unable to control ventilation




    • 4


    a A BPS score >5 indicates significant pain



    Table 22.2

    Critical-Care Pain Observation Tool (CPOT) a
























































    INDICATOR DESCRIPTION SCORE
    Facial expression Relaxed 0
    Tense 1
    Grimacing 2
    Body movements Absence 0
    Protection 1
    Restlessness 2
    Muscle tension Relaxed 0
    Tense, rigid 1
    Very tense, rigid 2
    Vent compliance
    or
    vocalization
    Tolerating 0
    Coughing 1
    Fighting 2
    Talking normally 0
    Sighing, moaning 1
    Crying out, sobbing 2

    a A CPOT score ≥3 indicates significant pain




  • Pharmacologic management ( Tables 22.3 and 22.4 )



    Table 22.3

    Opiates Commonly Used in the ICU

    Drugs without brand names are denoted by generic name only

































    DRUG USUAL DOSE PD/PK (IV) METABOLISM COMMENTS



    • Fentanyl



    • (Sublimaze)




    • Start at 0.5 mcg/kg/h



    • Titrate by 0.25 mcg/kg/h q15min to CPOT <3 or BPS ≤5



    • Usual maximum: 5 mcg/kg/h




    • Onset: 1–2 min



    • Duration: 0.5–1 h



    • Half-life: 2–4 h




    • Hepatic CYP3A4 major substrate




    • Accumulates in hepatic failure



    • Prolonged half-life with infusion duration



    • Muscle rigidity <1%




    • Morphine




    • Start at 2 mg/h



    • Titrate by 2 mg/h Q15min to CPOT <3 or BPS ≤5



    • Usual maximum: 20 mg/h




    • Onset: 5–15 min



    • Duration: 3–5 h



    • Half-life: 3–4 h




    • Glucuronidation




    • Hypotension and bradycardia from histamine release



    • Active metabolites, morphine-3-glucuronide (45–55%) and morphine-6 glucuronide (10–15%), accumulate in renal failure




    • Hydromorphone (Dilaudid)




    • Start at 0.25 mg/h



    • Titrate by 0.25 mg/h q15min to CPOT <3 or BPS ≤5



    • Usual maximum: 2 mg/h




    • Onset: 5–15 min



    • Duration: 3–4 h



    • Half-life: 2–3 h




    • Glucuronidation




    • Accumulates in hepatic failure




    • Remifentanil (Ultiva)




    • LD 1.5 mcg/kg; followed by 0.5 mcg/kg/h



    • Titrate by 0.5 mcg/kg/h q5min to CPOT <3 or BPS ≤5



    • Usual maximum: 15 mcg/kg/h




    • Onset: 1–3 min



    • Duration: 3–10 min



    • Half-life: 10–20 min




    • Blood and tissue esterases




    • Muscle rigidity >10%



    • Rebound pain and withdrawal symptoms due to quick offset


    BPS , Behavioral Pain Scale; CPOT , Critical-Care Pain Observation Tool; ICU , Intensive care unit; IV : Intravenously; LD : Loading dose; PD/PK : Pharmacodynamics/pharmacokinetics


    Table 22.4

    Non-Opioid Adjunctive Pain Medications















































    DRUG USUAL DOSE PD/PK METABOLISM COMMENTS



    • Acetaminophen (Ofirmev)




    • IV: 650 mg q4h–1 g q6h




    • Onset: 5–10 min



    • Half-life: 10–20 min




    • Glucuronidation, sulfonation




    • CI in severe hepatic disease




    • Ketorolac (Toradol)




    • IM/IV: 30 mg then 15–30 mg q6h up to 5 days




    • Onset: 10 min



    • Half-life: 2.4–8.6 h




    • Hydroxylation, conjugation/renal excretion




    • Use with caution in renal/hepatic dysfunction



    • May increase risk of ARF, bleeding, or GI ADR




    • Gabapentin (Neuronton)




    • PO: 300–600 mg/day÷2–3 doses




    • Onset: N/A



    • Half-life: 5–7 h




    • Renal excretion




    • Renally adjust



    • For neuropathic pain




    • Carbamazepine (Tegretol)




    • PO: 50–100 mg BID




    • Onset: 1–3 min



    • Half-life: 25–65 h then 12–17 h




    • Oxidation




    • For neuropathic pain



    • Caution in hepatic impairment



    • Strong inducer of CYP enzymes, substrate of CYP3A4



    • ADR: SJS, TEN, pancytopenia, SIADH




    • Pregabalin




    • PO: 75–200 mg BID




    • Onset: days



    • Half-life: 6 h




    • Urine (90% unchanged drug)




    • For neuropathic pain




    • Ketamine (Ketalar)




    • IV: 0.5 mg/kg ×1 LD then 1–2 mcg/kg/min




    • Onset: 30 s



    • Half-life:




      • alpha: 10–15 min



      • beta: 2.5 h





    • N-dealkylation, hydroxylation, conjugation




    • ADR >10%: confusion, irrational behavior, excitement, delirium, hallucinations



    • For postsurgical patients to reduce opioid consumption




    • Notes:



    • Non-opioid adjunctive pain medications to be used in combination with opioids to reduce opioid use and optimize analgesia

    Only gold members can continue reading. Log In or Register to continue

Feb 28, 2021 | Posted by in EMERGENCY MEDICINE | Comments Off on Pain, agitation, delirium, and neuromuscular blockade in the intensive care unit (ICU)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access